News

Newsletter

November 19, 2020

ANVISA decides that a patent application related to pharmaceutical use of cannabinoids is not to be deemed as against public health

On November 17th, 2020, ANVISA’s Board of Directors (BoD) unanimously granted an administrative appeal for reassessment of prior consent of a patent application for an invention covering several cannabinoids (including THC) for pain treatment. The BoD considered that mere use of cannabinoids within the invention is not to be deemed as a threat to public health.
 
ANVISA’s BoD unanimously granted the administrative appeal and ordered COOPI to reassess the case. Rapporteur Director Antonio Barra Torres understood that denying prior consent only because an invention comprises the use of cannabinoids disregards relevant legal and sanitary aspects that should be taken into account. Director Alessandra Bastos Soares also noted that ANVISA’s Intellectual Property Coordination Office (COOPI) must take note of what has been decided by BoD on the subject, which is of great importance.
 
For further information, access here our full newsletter.
Back

Last related news

November 22, 2021

Kasznar Leonardos receives ISO 9001 certification of quality

The ISO 9001 standard recognizes operational efficiency, focusing specifically on excellent customer service and continual process improvement. Our firm has received ISO Kasznar Leonardos receives ISO 9001 certification of quality

  • Kasznar Leonardos
  • Ler notícia

    November 12, 2021

    BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities

    By Flávia Tremura and Isabella Faccioli From November 2021 the BPTO will start to accept the right of precedence of the trademark BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities

  • Kasznar Leonardos
  • Ler notícia

    September 3, 2021

    The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

    On Sept. 2nd, 2021, Law No 14,200 was enacted to amend the Brazilian Patent & Trademark Act (BPTA) in order to change The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

    Ler notícia